Minhee Kang1, Triin Umbleja1, Grant Ellsworth2, Judith Aberg3, Timothy Wilkin2. 1. Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA. 2. Division of Infectious Diseases, Weill Cornell Medicine, New York, NY; and. 3. Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
BACKGROUND: We compared antibody (Ab) responses to a quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) vaccine between men and women with HIV-1. METHODS: A retrospective analysis of participant-level data from published clinical trials of HPV vaccine administered at study entry and at weeks 8 and 24 was conducted separately for baseline Ab undetectable and baseline Ab detectable using Ab titers and titer changes from baseline, respectively, at week 28 and year 1.5. Generalized estimating equations accounted for multiple HPV types and were adjusted for multiple baseline factors, including existing HPV antibodies before vaccination from natural exposure. RESULTS: We evaluated 575 participants with CD4+ count >200 cells/mm3, 323 men and 252 women: median ages 46 and 38 years, respectively. Week 28 and year 1.5 Ab titers were similar between men and women regardless of the baseline Ab detection in multivariate models. HIV-1 RNA ≥400 copies/mm3 was associated with a lower week 28 Ab response; in baseline Ab detectable, the baseline HPV Ab titer level, HPV DNA detection, and lower CD4+/CD8+ ratio were also associated with a lower response. CD4+/CD8+ ratio was a stronger predictor in the year 1.5 Ab analysis than in the week 28 analysis. Ab responses among baseline Ab detectable were only somewhat higher than those among baseline Ab undetectable (eg, type 16 week 28 median 3.46 vs 3.20 log10 mMU/mL) despite the existing baseline titer (median 1.74). CONCLUSIONS: We did not find any sex differences of serologic response to HPV vaccine. Ab titer gain was lower in those with preexisting antibodies due to previous natural infection.
BACKGROUND: We compared antibody (Ab) responses to a quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) vaccine between men and women with HIV-1. METHODS: A retrospective analysis of participant-level data from published clinical trials of HPV vaccine administered at study entry and at weeks 8 and 24 was conducted separately for baseline Ab undetectable and baseline Ab detectable using Ab titers and titer changes from baseline, respectively, at week 28 and year 1.5. Generalized estimating equations accounted for multiple HPV types and were adjusted for multiple baseline factors, including existing HPV antibodies before vaccination from natural exposure. RESULTS: We evaluated 575 participants with CD4+ count >200 cells/mm3, 323 men and 252 women: median ages 46 and 38 years, respectively. Week 28 and year 1.5 Ab titers were similar between men and women regardless of the baseline Ab detection in multivariate models. HIV-1 RNA ≥400 copies/mm3 was associated with a lower week 28 Ab response; in baseline Ab detectable, the baseline HPV Ab titer level, HPV DNA detection, and lower CD4+/CD8+ ratio were also associated with a lower response. CD4+/CD8+ ratio was a stronger predictor in the year 1.5 Ab analysis than in the week 28 analysis. Ab responses among baseline Ab detectable were only somewhat higher than those among baseline Ab undetectable (eg, type 16 week 28 median 3.46 vs 3.20 log10 mMU/mL) despite the existing baseline titer (median 1.74). CONCLUSIONS: We did not find any sex differences of serologic response to HPV vaccine. Ab titer gain was lower in those with preexisting antibodies due to previous natural infection.
Authors: Timothy Wilkin; Jeannette Y Lee; Shelly Y Lensing; Elizabeth A Stier; Stephen E Goldstone; J Michael Berry; Naomi Jay; David Aboulafia; David L Cohn; Mark H Einstein; Alfred Saah; Ronald T Mitsuyasu; Joel M Palefsky Journal: J Infect Dis Date: 2010-10-15 Impact factor: 5.226
Authors: Keith S Reisinger; Stan L Block; Eduardo Lazcano-Ponce; Rudiwilai Samakoses; Mark T Esser; Joanne Erick; Derek Puchalski; Katherine E D Giacoletti; Heather L Sings; Suzanne Lukac; Frances B Alvarez; Eliav Barr Journal: Pediatr Infect Dis J Date: 2007-03 Impact factor: 2.129
Authors: Erna Milunka Kojic; Minhee Kang; Michelle S Cespedes; Triin Umbleja; Catherine Godfrey; Reena T Allen; Cynthia Firnhaber; Beatriz Grinsztejn; Joel M Palefsky; Jennifer Y Webster-Cyriaque; Alfred Saah; Judith A Aberg; Susan Cu-Uvin Journal: Clin Infect Dis Date: 2014-04-09 Impact factor: 9.079
Authors: Francisco Fuster; Jose Ignacio Vargas; Daniela Jensen; Valeska Sarmiento; Pedro Acuña; Felipe Peirano; Felipe Fuster; Juan Pablo Arab; Felipe Martínez Journal: Vaccine Date: 2016-03-02 Impact factor: 3.641
Authors: Takehiro Takahashi; Mallory K Ellingson; Patrick Wong; Benjamin Israelow; Carolina Lucas; Jon Klein; Julio Silva; Tianyang Mao; Ji Eun Oh; Maria Tokuyama; Peiwen Lu; Arvind Venkataraman; Annsea Park; Feimei Liu; Amit Meir; Jonathan Sun; Eric Y Wang; Arnau Casanovas-Massana; Anne L Wyllie; Chantal B F Vogels; Rebecca Earnest; Sarah Lapidus; Isabel M Ott; Adam J Moore; Albert Shaw; John B Fournier; Camila D Odio; Shelli Farhadian; Charles Dela Cruz; Nathan D Grubaugh; Wade L Schulz; Aaron M Ring; Albert I Ko; Saad B Omer; Akiko Iwasaki Journal: Nature Date: 2020-08-26 Impact factor: 49.962